Compare Alcon AG (ALC) vs CleanSpark Inc (CLSK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs CleanSpark Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while CleanSpark Inc trades at $12.38 (market cap $3.20B). The key difference: Alcon AG is far larger — about 10.2× CleanSpark Inc's market cap, and Alcon AG pays a 0.54% dividend while CleanSpark Inc pays none. Which is the better fit depends on your goals.
| ALC | CLSK | |
|---|---|---|
Market Cap | $32.69B | $3.20B |
Sector | Health | Technology |
52-Week High | $92.22 | $23.20 |
52-Week Low | $62.02 | $8.18 |
Enterprise Value | $36.28B | $4.06B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
CleanSpark (CLSK) trades at $13.51, up 7.05% today but facing bearish technical signals with recent earnings misses. The company reported strong revenue growth to $766M in 2025 but swung to a net loss margin of -67.66% in 2026. Analyst sentiment remains strongly bullish with 11 buy ratings and a $20.50 consensus target, though cash flow challenges persist with negative operating cash flow of $461M in 2025.
The stock presents a divergence between strong analyst support and challenging fundamentals. While Wall Street sees 100% upside potential, investors face execution risks from profitability challenges and volatile bitcoin mining economics. The technical setup suggests near-term pressure with the stock trading near support levels amid broader market uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About CleanSpark Inc
CleanSpark is a leading Bitcoin mining company that operates high-density data centers. It focuses on using sustainable energy to power its mining fleet and provides digital infrastructure for the blockchain ecosystem.
Read more on CLSK →
